Last Price
9.99
Today's Change
-0.35 (3.38%)
Day's Change
9.70 - 11.10
Trading Volume
5,764,022
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Linda Marbán Ph.D. Dr. Linda Marbán Ph.D.
Full Time Employees: 101 101
IPO Date: 2007-02-13 2007-02-13
CIK: 0001133869 0001133869
ISIN: US14070B3096 US14070B3096
CUSIP: 14070B309 14070B309
Beta: 3.92 3.92
Last Dividend: 0.00 0.00
Dcf Diff: 5.21 5.21
Dcf: -0.17 -0.17
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.